Login
Companies $GKOS
$244.88 +$0.00 (0.0%) After hours
GLAUKOS Corp logo

GLAUKOS Corp

glaukos.com

What Do They Do?

Sells glaucoma devices and medicines and corneal therapies to eye-care providers, while developing treatments for retinal disease.

How Do They Make Money?

Customers buy eye-care products; the company charges for products delivered, then collects under invoice terms.

revenue
SegmentShareRevenue
Glaucoma
Sold outright

83%
FY2022: 76%
Corneal Health
Sold outright

17%
FY2022: 24%

Who Are Their Customers?

Ophthalmic surgeons and other eye-care professionals are the sales audience; ambulatory surgery centers, hospitals and private practices are primary customers. U.S. sales are mainly direct, while international sales run mostly through direct subsidiaries, with independent distributors in some countries.

Do Revenues Turn Into Profits?

No. It lost $187.7M in FY2025.

Operating income, FY2025
−39% of revenue
▼ −63% (Loss) vs FY2024 (−$122.4M, −32%)
Net income, FY2025
−37% of revenue
▼ −28% (Loss) vs FY2024 (−$146.4M, −38%)
Free cash flow, FY2025
−4% of revenue
▲ +67% (Loss) vs FY2024 (−$67.6M, −18%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +58%
vs $133.5M in Q3 FY2025
Net income
▲ Turned profitable
vs −$16.2M in Q3 FY2025
Glaucoma share of revenue vs 82.6% in Q3 FY2025
  • Jul 29, 2026 Raised 2026 revenue guidance to $680–$700 million The new range was up from $620 - $635 million, with expected contributions from iDose TR, Epioxa and iStent infinite.

Growing. Revenue grew 73% in 4 years, from $294M in FY2021 to $507.4M in FY2025, about 15% a year.

iDose becomes a commercial product The glaucoma portfolio has moved from an investigational implant to a marketed procedural drug: iDose TR is now commercialized alongside the stent products.

Epioxa advances to approval The corneal business has moved beyond epi-off therapy and clinical work on epi-on: Epioxa is approved and launch preparation is underway.

Revenue over time
Glaucoma Corneal Health
$1B$500M$0

Who Do They Compete With?

Competes with Alcon, Sight Sciences, AbbVie, Iantrek, New World Medical, Epion Therapeutics, PeschkeTrade, Johnson & Johnson, Novartis, Genentech/Roche, Regeneron Pharmaceuticals, and Bayer

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support